Browse by Tags

AREVA Med’s new clinical trial website, www.TargetedTrials.com, provides a comprehensive source of information for patients and physicians searching for innovative oncology trials. Visitors will find information that describes the therapy, abdominal cancers, the clinical trial process and eligibility...

On July 7, 2011, the University of Alabama at Birmingham started recruiting patients for AREVA Med’s ²¹²Pb-TCMC-Trastuzumab radioimmunotherapy Phase I clinical trial using Lead-212 (212Pb). Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop...

You may not often put the two words “nuclear” and “medicine” together, but AREVA has, and opened a new front in the battle against cancer with the innovation and development of a promising treatment using Lead-212, a byproduct of used nuclear fuel recycling. Production of medical-grade Lead-212 by AREVA...

In the battle against cancer, AREVA Med is glad to announce the “public hearing” period for the construction of AREVA Med’s new lead-212 isotopes production facility was successfully completed on March 15, 2011. We are now on the threshold of constructing this unique facility at AREVA’s Bessines site...

AREVA announced today that its subsidiary AREVA Med, which specializes in nuclear medicine, has received authorization from the Food and Drug Administration (FDA) to begin U.S. clinical trials for a new treatment aimed at combating cancer. This is the first such authorization for clinical trials using...

Bringing industry and medicine together in the battle against cancer, AREVA Med has announced another important milestone to continue this fight. AREVA Med, an AREVA subsidiary, is dedicated to developing medical grade lead-212 isotopes to be used in promising Radioimmunotherapy. Lead-212 is a rare radioactive...

AREVA subsidiary AREVA Med and the University of Cincinnati, Ohio, announced today that they have signed a research agreement to develop a new treatment to combat cancer. Under the agreement, AREVA will provide the medical-grade isotope Lead-212 to the university for researchers to conduct studies on...

AREVA Med, an AREVA subsidiary, announced today the future construction of a facility in France that will produce on a large-scale medical grade lead 212. Why Lead-212? Lead-212 is a rare radioactive isotope that lies at the heart of promising nuclear medical research to develop new cancer treatments...

p>We have discussed our efforts in nuclear medicine and the AREVA Med project a couple of times on the blog before, and now I am very pleased tell you about our new website, www.arevamed.com. Here you will be able to discover more information on the project’s history, basic and technical merit. Through...

by Katherine Berezowskyj Last week France’s TF1 television network featured AREVA’s innovative work under way in partnership with the U.S. National Cancer Institute and the University of Alabama for the development of a treatment to fight cancer. The news team got to take a look inside AREVA’s La Hague...

And if the AREVA Med recognition at the CGI event has you curious for more background on this effort, do see the interview with CEO Patrick Bourdet here: http://djysrv.blogspot.com/2009/05/areva-enters-nuclear-medicine-market.html ...read more

Today in New York, the Clinton Global Initiative (CGI) recognized AREVA and its subsidiary AREVA Med LLC for its pioneering work in developing new methods for producing medical-grade Lead 212─ an isotope that could someday be used in promising cancer treatments. As the world leader in clean energy generation...

Announced today, AREVA has formed a new company dedicated to the development of powerful new anti-cancer treatments. AREVA Med LLC will work to target aggressive forms of cancer that currently have limited treatment options. If successful in clinical trails, the new treatments would be used in advanced...